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Leukocyte depletion during cardiopulmonary bypass has been demon- 
strated in animal experiments o improve pulmonary function. Conflicting 
results have been reported, however, with clinical depletion by arterial ine 
filter of leukocytes at the beginning of cardiopulmonary bypass. In this 
study, we examined whether leukocyte depletion from the residual heart- 
lung machine blood at the end of cardiopulmonary b pass would improve 
lung function and reduce the postoperative inflammatory response. Thirty 
patients undergoing elective heart operations were randomly allocated to a 
leukocyte-depletion group or a control group. In the leukocyte-depletion 
group (n = 20), all residual blood (1.2 to 2.1 L) was filtered by leukocyte- 
removal filters and reinfused after cardiopulmonary b pass, whereas in the 
control group an identical amount of residual blood after cardiopulmonary 
bypass was reinfused without filtration (n = 10). Leukocyte depletion 
removed more than 97% of leukocytes from the retransfused blood (p < 
0.01) and significantly reduced circulating leukocytes (p < 0.05) and 
granulocytes (p < 0.05) compared with the control group. Levels of the 
inflammatory mediator thromboxane B 2 determined at the end of operation 
(p < 0.05) were significantly lower in the depletion group than in the 
control group, whereas no statistical differences in interleukin-6 levels were 
found between the two groups. After operation, pulmonary gas exchange 
function (arterial oxygen tension at a fraction of inspired oxygen of 0.4) was 
significantly higher in the leukocyte-depletion group 1 hour after arrival to 
the intensive care unit (p < 0.05) and after extubation (p < 0.05). There 
were no statistical differences between the two groups with respect to 
postoperative circulating platelet levels and blood loss, and no infections 
were observed uring the whole period of hospitalization. These results 
suggest hat leukocyte depletion of the residual heart-lung machine blood 
improves postoperative lung gas exchange function a d is safe for patients 
who are expected to have a severe inflammatory response after heart 
operations. (J Thorac Cardiovasc Surg 1996;112:494-500) 
C ardiopulmonary bypass (CPB) induces a whole- 
body inflammatory response that leads to post- 
operative lung dysfunction. 1'2 This response is 
largely mediated by the activation of polymorpho- 
From the Departments of Cardiothoracic Surgery a and Anesthe- 
siology, b University Hospital, Groningen, The Net rlands. 
Received for publication Sept. 19, 1995; revisions requested Nov. 
21, 1995; revisions received Dec. 14, 1995; accepted for 
publication Dec. 21, 1995. 
Address for reprints: W. van Oeveren, PhD, Blood Interaction 
Research, Department of Cardiothoracic Surgery, University 
Hospital Groningen, 59 Oostersingel, 9713 EZ Groningcn, 
The Netherlands. 
Copyright © 1996 by Mosby-Year Book, Inc. 
0022-5223/96 $5.00 + 0 12/1/71449 
494 
nuclear leukocytes and by subsequent leukocyte 
deposition and interaction with the lung endotheli- 
um. 3-7 During the initial phase of CPB, leukocytes 
are activated by contact of blood with foreign ma- 
terials in the extracorporeal circuit. After release of 
the aortic crossclamp in the late phase of CPB, when 
heart and lungs are reperfused, activation of leuko- 
cytes and leukocyte-endothelium interaction are in- 
tensified, leading to the impairment of lung function 
and the induction of a postoperative inflammatory 
response known as the "postperfusion syn- 
drome.,,a, 9 
Leukocyte depletion by means of filtration was 
originally used by blood banks to prevent transfu- 
sion complications associated with donor leuko- 
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cytes.10, 11 Recent animal experiments demonstrated 
that leukocyte depletion in different heart operation 
models reduces heart and lung reperfusion inju- 
ry. 12-14 Conflicting results have been noted, how- 
ever, in reports of clinical use at the beginning of 
CPB of arterial line filters with leukocyte-depleting 
capacityJ 5~9 Furthermore, there has been concern 
regarding the simultaneous removal of platelets 
during leukocyte depletion, which could influence 
postoperative hemostasisJ  3'20 
In this article, we report a study in which only the 
blood residual in heart-lung machine was depleted 
of leukocytes, because this blood contains a consid- 
erable number of activated leukocytes and is usually 
reinfused to patients immediately after CPB. We 
examined whether leukocyte depletion of the resid- 
ual blood at the end of CPB would improve postop- 
erative lung function and reduce the postoperative 
inflammatory response. We also examined whether 
such a "partial" leukocyte-depletion method would 
minimize the major side effect of leukocyte deple- 
tion in patients undergoing heart operations, reduc- 
tion of circulating platelets. 
Patients and methods 
Patients. After approval by the medical ethical com- 
mittee in the University Hospital in Groningen and in- 
formed consent from patients, 30 patients electively un- 
dergoing either coronary artery bypass grafting, heart 
valve replacement, or a combined procedure were ran- 
domly allocated to a leukocyte-depletion group (n = 20) 
or a control group (n = 10). Exclusion criteria were a 
history of allergy or recurrent infection, reoperation, and 
emergency operation. The demographic data of patients 
in both groups are summarized in Table I. 
Anesthesia was induced and maintained by intravenous 
infusion of sufentanil citrate (1 to 3/xg/kg) and midazolam 
(0.05 to 0.1 mg/kg). Muscle relaxation was achieved with 
pancnronium bromide (100 to 140/xg/kg). Cefamandol at 
a dose of 2 gm and dexamethason at a dose of 1 mg/kg 
were administered after induction. Anticoagnlation was 
achieved by intravenous administration of bovine lung 
heparin at a dose of 300 IU/kg about 5 minutes before the 
start of CPB. 
CPB. The extracorporeal circuit consisted of roller 
pumps (St6ckert Instrnmente GMBH, Munich, Germany) 
and a microporous polypropylene membrane oxygenator 
(CML Excel; Cobe Laboratories Inc., Lakewood, Colo.). 
Within 10 minutes of CPB initiation at a flow rate at 
2.4 L × rain -1 • m 2, the aorta was crossclamped and 1 L 
St. Thomas' cardioplegic solution (4 ° C) was infused into 
the aortic root to provide myocardial preservation. During 
CPB, moderate hypothermia was induced to maintain the 
nasopharyngeal temperature between 28 ° to 30 ° C. The 
mean arterial pressure was maintained at 50 to 60 mm Hg 
during CPB. Anticoagulation during CPB was monitored 
by the Ceiite activated clotting time (International Tech- 
Table I. Patient demographic information 
Control Depletion 
(n = 10) (n = 20) 
Age (yr) 62 -+ 13 60 _+ 11 
Sex (n) 
Male 8 14 
Female 2 6 
Height (cm) 173 _+ 8 172 _+ 10 
Weight (kg) 80 -+ 14 77 ± 11 
Body surface (m 2) 1.97 ± 0.22 1.91 ± 0.16 
CABG (n) 8 14 
AVR (n) - -  5 
MVR (n) 1 - -  
CABG + AVR (n) 1 - -  
CABG + MVR (n) - -  1 
Values expressed asmean ± standard deviation of the mean. CABG, 
Coronary artery bypass grafting; AVR, aortic vane replacement; MVR, 
mitral valve replacement. 
nidyne Co., Edison, N.J.). After CPB, heparin was neu- 
tralized by protamine chloride (3 mg/kg). 
Leukocyte depletion. Leukocyte depletion was achieved 
with leukocyte-removal filters (RC400; Pall Biomedical, 
Portsmouth, U.K.) designed particularly for leukocyte filtra- 
tion under high-flow conditions in the operating room. 21 
After termination of CPB, a total volume of 1200 to 2100 ml 
residual blood in the extracorporeal circuit was collected into 
a blood transfusion bag. In the leukocyte-depletion group, 
the collected blood was filtered by two or three filters and 
reinfused before the end of operation, whereas in the control 
group the residual blood was reinfused through the venous 
transfusion line without leukocyte filtration. 
Lung function. Pulmonary gas exchange was measured 
by the partial arterial oxygen pressure from blood samples 
drawn from the radial artery line and standardized at a 
fraction of inspired oxygen of 0.4. Pulmonary hemodynam- 
ics, exemplified by mean pulmonary artery pressure (PAP) 
and pulmonary capillary wedge pressure (PCWP), were 
measured through aSwan-Ganz catheter (Baxter Healthcare 
Corp., Edwards Division, Irvine, Calif.) introduced percuta- 
neously through the right internal jugular vein into the 
pulmonary artery. Pulmonary vascular resistance (PVR) was 
calculated according to the following formula: PVR 
(dyne.sec-cm 5) = (pAP _ PCWP)/CO x 80. 
Other clinical parameters. Duration of postoperative 
intubation was recorded uring each patient's tay in the 
intensive care unit. Blood loss was indicated by 24-hour 
chest drainage. In addition, durations of stay in the 
intensive care unit and of hospitalization after operation 
were obtained from hospital registration records. 
Laboratory parameters. For laboratory hematologic 
tests and biochemical assays, blood samples were taken 
from the indwelling radial arterial catheter at the baseline 
before operation, at the end of CPB before transfusion of 
the leukocyte-depleted blood, at the end of operation 
during skin closure, 1 hour and 3 hours after the patient's 
arrival in the intensive care unit, and at 6 AM the next day 
in the intensive care unit. In addition, prefiltration and 
postfiltration samples were taken from the transfusion 
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Fig. 1. Circulating leukocytes, granulocytes, lymphocytes 
and platelets in patients with and without leukocyte 
depletion of the reinfused heart-lung machine blood after 
the end of CPB. Arrow indicates the start of depletion; 
asterisk represents p < 0.05 between the two groups. 
pre-op, Before operation; end-op, at end of operation 
during skin closure; ICU, intensive care unit. 
bags to determine the cell counts and calculate the rate of 
leukocyte removal. 
Cell counts were determined by a cell counter (Cell- 
Dyn 610; Abbot, Santa Clara, Calif.) with a dilution of 
1:250 for counting leukocytes and granulocytes and of 
1:25,000 for counting platelets. For the postfiltration 
samples, leukocytes were counted by means of a Nageotte 
manual counting chamber or by the cell counter with a 
dilution of 1:100. 
For biochemical ssays, plasma was obtained by centrif- 
ugation of whole blood at 1100 g and stored at -80 ° C for 
further determinations. Thromboxane was determined by 
enzyme immunoassay (Cayman Chemical Company, Ann 
Arbor, Mich.) in plasma anticoagulated with citrate and 
indomethacin. Interleukin-2 and interleukin-6 were deter- 
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Fig. 2. Arterial partial oxygen pressure (Pao2) deter- 
mined after arrival in the intensive care unit (ICU) and 
after extubation in patients receiving leukocyte-depleted 
residual blood (n = 20) and in patients receiving nonde- 
pleted residual blood (n = 10). The fraction of inspired 
oxygen was standardized at40%. Asterisk represents p < 
0.05 between the two groups. 
mined by enzyme immunoassay (Quantikine; R&D Sys- 
tems Inc., Minneapolis, Minn.) from citrated plasma. 
Statistics. Data processing and statistical tests were 
performed with StatView software (Abacus Concepts, 
Inc., Berkeley, Calif.) Data are expressed as mean plus or 
minus standard error of the mean unless otherwise indi- 
cated. A repeated-measures analysis of variance was used 
to determine the difference between the two groups. 
Student's t test or Mann-Whitney test was used for 
analysis of differences between the two groups at each 
sampling or recording time point. Ap  value less than 0.05 
was considered statistically significant. 
Results 
There were no significant differences between the 
leukocyte-depletion group and the control group 
with respect to duration of CPB and aortic cross- 
clamp time. All patients recovered uneventfully 
after operation. 
Leukocyte reduction in residual machine blood. 
The average leukocyte count in the residual ma- 
chine blood before filtration was 5.76 _+ 0.44 × 109 
cells/L. After filtration, the count was 0.152 _+ 
0.01 × 109 cells/L. More than 97% of the leukocytes 
were removed from the residual blood in the leuko- 
cyte-depletion group. The average platelet count 
from the machine blood before filtration was 107 __ 
6 × 109 cells/L; after filtration, it was 43 + 2 × 10 9 
cells/L. About 60% of the platelets in the machine 
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Table II. Inflammatory mediators before and after operation 
Parameter Before CPB End CPB End operation ICU 1 hr ICU 3 hr POD 1 
Thromboxane (pg/mI) 
Depletion ND 48 -+ 15 48 -+ 9* 33 -+ 7 23 -+ 29 19 -+ 26 
Control ND 62 -+ 96 127 _+ 63 48 -+ 15 59 -+ 56 21 -+ 34 
Interleukin-6 (pg/ml) 
Depletion 36 + 14 126 _+ 96 ND 393 +_ 116 344 -+ 90 125 -+ 46 
Contro! 20 -+ 24 197 _ 246 ND 208 = 103 260 -+ 38 155 -+ 29 
Interteukin-2 (pg/ml) 
Depletion UD UD ND UD UD UD 
Control UD UD ND UD UD UD 
Values are expressed as the geometric mean and the standard error of the mean. ICU, Intensive care unit; POD, postoperative day; ND, not determined; UD, 
undetectable (below the lowest detectable vel stated by the manufacturer). 
*p < 0.05 compared with control. 
Table III. Pulmonary hemodynamics 
Before End End 
Parameter CPB CPB AP operation 
PAP (mm Hg) 
Depletion 
Control 




(dyne" sec -1.  cm -5) 
Depletion 
Control 
16-+1.1 17-+1.0 14-+1.4 17-+1.1 
17-+0.9 20-+0.7 19-+0.7 21-+1.0 
10-+0.9 12+-1.4 10-+1.5 10-+1.2 
12-+0.7 13-+1.1 11-+0.9 14-+1.3 
156 +34 129-+32 120-+23 173-+25 
145-+18 116-+22 103-+15 125--14 
AP, After protamine. Values expressed as mean _+ standard error of the 
mean. 
blood were removed by the filters in the leukocyte- 
depletion group. 
Circulating leukocytes and platelets. Circulating 
leukocyte and granulocyte counts at the end of 
operation were significantly less in the depletion 
group than in the control group (p < 0.05). There 
were no significant differences in circulating lym- 
phocyte and platelet counts between the two groups 
(Fig. 1). 
Inflammatory mediators. Thromboxane B 2 levels 
were significantly lower in the leukocyte-depletion 
group than in the control group at the end of 
operation (p < 0.05; Table II). Interleukin-6 levels 
increased in both the leukocyte-depletion and con- 
trol groups during the early postoperative period. 
No significant difference was found between the two 
groups. Interleukin-2 was not detectable in any of 
the samples. 
Lung function. Pulmonary gas exchange, mea- 
sured by partial arterial oxygen pressure, was signif- 
icantly higher in the leukocyte-depletion group than 
in the control group both at 1 hour after arrival in 
the intensive care unit (118 + 10 vs 86 -+ 10 mm Hg, 
Table IV. Perioperative and postoperative data 
Control Depletion 
(n = 10) (n = 20) 
CPB time (min) 100 _+ 24 94 _+ 38 
Crossclamp time (rain) 67 -+ 19 63 ± 29 
Blood loss (ml) 685 -- 79 587 -+ 87 
Intubation time (hr) 13.8 _+ 1.3 11.7 _+ 0.9 
ICU stay (days) 1.1 _+ 0.1 1.0 _+ 0.0 
Hospital stay (days) 8.7 _+ 2.1 7.3 _+ 0.5 
Values expressed as mean + standard deviation of the mean. ICU, 
Intensive care unit. 
p < 0.05) and immediately after extubation (120 _+ 
8 vs 89 _+ 10 mm Hg, p < 0.05; Fig. 2). PAP was 
somewhat lower in patients receiving leukocyte- 
depleted blood than in the control group, but this 
difference in PAP was not significant. Similarly, 
there were no statistical differences in PCWP and 
PVR between the two groups (Table III). 
Other clinical outcomes. There was no significant 
difference between the two groups with respect o 
postoperative blood loss recorded from the chest 
drainage tube until the first postoperative morning. 
Duration of intubation after operation was slightly 
shorter in the leukocyte-depletion group than in the 
control group, but this difference was not statisti- 
cally significant. Similarly, no statistical difference 
was found between the two groups regarding the 
duration of intensive care unit and hospital stays 
(Table IV). 
Discussion 
Leukocyte depletion from systemic circulation 
during CPB has been reported to reduce free radi- 
cal-mediated lung injury and granulocyte-mediated 
ventricular dysfunction in animal experiments. 1214 
Clinically, however, leukocyte depletion with an 
arterial ine filter at the beginning of CPB has not 
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achieved the goals of reducing intraoperative and 
postoperative l ukocytosis and of improving lung 
function after heart operations. 15-19 In this study, we 
have demonstrated that leukocyte depletion of only 
1.2 to 2.1 L residual heart-lung machine blood 
significantly attenuates postoperative l ukocytosis 
and improves pulmonary gas exchange function in 
patients undergoing heart operations. Of more im- 
portance, because this blood is usually transfused 
through the venous line without any substantial 
filtration, leukocyte depletion in this setting may 
provide a local protective ffect for the lungs, even if 
the amount is relatively small. 
There are at least two reasons why leukocyte 
depletion of the residual heart-lung machine blood 
may protect he lung. First, we observed in a recent 
study 22 that the residual heart-lung machine blood 
contained higher levels of leukocyte-re!ease prod- 
ucts than seen in the systemic irculation, suggesting 
that the leukocytes remaining in the heart-lung 
machine are highly activated. Second, it is known 
that the heart-lung machine blood contains a num- 
ber of foreign substances, aswell as microaggregates 
formed mainly by platelets and leukocytes. 23' 24 Dur- 
ing CPB, the blood is returned to patients from the 
arterial side of the heart-lung machine, where an 
arterial line filter removes microaggregates. After 
CPB, however, the residual heart-lung machine 
blood is reinfused to patients by intravenous trans- 
fusion without any substantial filtration (usually only 
a clot filter with a large pore size is used). Because 
the lung is anatomically located to receive all the 
reinfused blood from the venous side, lung injury 
may occur as a result of the pulmonary accumula- 
tion of microaggregates 25' 26 mediated by trapped 
platelets and leukocytes. 
In fact, current leukocyte-depleting filters remove 
no t only leukocytes but also other particles less than 
5/xm in diameter. It has been reported recently that 
a similar type of blood transfusion filter was able to 
remove the microfibrillar collagen hemostat from 
the wound blood harvested from the surgical field. 27 
Particulate microaggregates are continuously gener- 
ated during CPB; this is particularly evident in the 
cardiotomy return line. 23 These microaggregates are 
mostly smaller than 30/xm in diameter 23 and are not 
always caught by the cardiotomy filter, which usually 
has a pore size between 20 and 40 /xm. 2a Because 
the residual machine blood collected at the end of 
CPB contains a large portion of blood from the 
cardiotomy reservoir, filtration with a leukocyte- 
removal filter may prevent any particulates larger 
than 5 /xm from being retransfused to patient, 
reducing lung injury. 
Although a direct comparison of our results with 
results obtained from arterial ine leukocyte deple- 
tion is unjustified, it does appear that leukocyte 
depletion of the residual machine blood is more 
likely to have a local effect on protecting the lungs. 
In addition, leukocyte depletion with transfusion 
filters may have other advantages in clinical appli- 
cation. The procedure is easy to handle because the 
filter can be installed at any time before use without 
flush or priming. Moreover, it could serve as an 
optional intervention method that can be added at 
the end of CPB according to the patient's clinical 
condition, particularly for patients with a longer 
duration of CPB and a predicted strong postopera- 
tive inflammatory esponse. One potential disadvan- 
tage of this method, however, is the limited blood 
volume available for filtration, which depends on 
the volume of residual blood in the heart-lung 
machine. 
The inflammatory mediator thromboxane B 2 is 
usually increased uring and after CPB in patients 
undergoing heart operations. 29 In this study, we 
observed a significantly reduction of plasma throm- 
boxane B 2 at the end of operation in the leukocyte- 
depletion group compared with the control group; 
this difference can be explained by the removal of 
activated leukocytes and the simultaneous removal 
of platelets after the end of CPB. We also measured 
interleukin-6 and interleukin-2; the former is a 
marker of acute-phase r sponse produced by mono- 
nuclear phagocytes and the latter is mainly pro- 
duced by lymphocytes. 3° We confirmed that the 
peak release of interleukin-6 occurred about 1 hour 
after arrival in the intensive care unit, as reported by 
other groups. 31 No significant difference was found 
between the depletion and the control groups, how- 
ever, which suggest that leukocyte depletion in this 
setting has no effect on the release of interleukin-6 
during the early postoperative p riod. Interleukin-2 
was not detectable in any samples, indicating that 
there was no lymphocyte-associated release of cyto- 
kines in these patients. This is in agreement with a 
recent report that interleukin-2 could be detected 
only occasionally after heart operations. 32
One of the concerns regarding leukocyte deple- 
tion during heart operations i that the simultaneous 
removal of platelets 13' 17 might affect postoperative 
hemostasis. In this study, little influence on circulat- 
ing platelet count was observed in patients receiving 
leukocyte-depleted blood, although considerable 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 112, Number 2 
Gu et aL 4 9 9 
numbers of platelets were removed from the rein- 
fused heart-lung machine blood. Consistently, there 
was no significant difference between the two groups 
with respect o the postoperative blood loss. On the 
other hand, it remains to be elucidated whether 
removal of platelets from the residual heart-lung 
machine blood contributed to improved postopera- 
tive lung function. It is known that the platelets may 
deposit in the myocardium during reperfusion, 33' 34 
leading to myocardial reperfusion injury. 35 More- 
over, release products from platelets uch as platelet 
activating factor and platelet associated adhesive 
molecules may further activate leukocytes and pro- 
mote leukocyte adhesion to the endothelium. 3638 
This mechanism ay also operate in initiating lung 
injury because platelet deposition occurred similarly 
during lung reperfusion in the lung microvascula- 
ture. 39 
In conclusion, leukocyte depletion of residual 
heart-lung machine blood at the end of CPB im- 
proves postoperative lung gas exchange function 
and reduces postoperative l ukocytosis. Further- 
more, leukocyte depletion in this setting did not 
result in any postoperative complications with re- 
spect to hemostasis and infection. Further investi- 
gations hould be carried out to compare the differ- 
ent leukocyte-depletion methods with respect to 
clinical benefits and costs, and to determine which 
patient populations can profit most from this inter- 
vention. 
We thank the perfusion team and the intensive care 
unit nursing staff in the Thorax Center, University Hospi- 
tal Groningen, for collecting the clinical data and J. Haan 
in the Blood Interaction Research Lab for performing the 
biochemical assays. 
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